Acuitive Technologies

Key People

• Alex Khowaylo - Chief Executive Officer & Chairman of the Board
• David Washburn - Chief Operating Officer, Chief Financial Officer, Principal & Board Member
• Michael McCarthy - Managing Partner, CCO & Board Member
• James Malayter - Director & Board Member
• Matthew Poggie - Senior Vice President, Research & Development
• Rui Ferreira - Vice President, Product Development
• Richard Tran - Vice President, Research
• Ken Yuen - Director, Manufacturing
• Ken Barbour - Director, Supply Chain
• Mary Theresa Freeley - Director, Quality

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned professionals with extensive experience in the orthopedic industry, including multiple successful exits.

The executive team includes individuals with decades of experience in orthopedic financial, operations, and leadership positions, contributing to multiple successful company exits. This depth of experience positions the company favorably for strategic decision-making and execution.

Clinical Need

Aspect: Very Strong
Summary: CITREGEN addresses significant challenges in orthopedic surgery by replicating the intrinsic cellular support network.

The development of CITREGEN as a synthetic biomaterial designed to replicate the intrinsic cellular support network directly addresses critical issues in orthopedic surgery, offering a paradigm-changing solution to existing clinical problems.

Competition

Aspect: Somewhat crowded
Summary: The orthopedic device market is competitive, but CITREGEN offers a unique value proposition.

While the orthopedic device market is populated with numerous players, CITREGEN's innovative approach and material science technology provide a distinct advantage, though market penetration will require strategic efforts.

Technical Challenge

Aspect: Predictable
Summary: The development of CITREGEN involves complex material science, but the company's expertise mitigates risks.

The creation of CITREGEN entails sophisticated material science challenges; however, the experienced R&D team has demonstrated capability in navigating these complexities, reducing technical risk.

Patent

Aspect: Strong
Summary: The company holds multiple patents, providing a solid intellectual property foundation.

With 31 total patent documents, including 10 granted and 18 pending, the company has established a robust IP portfolio that enhances its competitive position and protects its innovations.

Financing

Aspect: Well-funded
Summary: Secured significant funding, including a $18.7M later-stage VC round in December 2023.

The company has successfully raised substantial capital, with the latest funding round amounting to $18.7 million, indicating strong investor confidence and providing resources for growth and development.

Regulatory

Aspect: 510k/PMA
Summary: The company is pursuing necessary regulatory approvals for its products.

Navigating the regulatory landscape is critical for product commercialization. The company's efforts in obtaining 510(k) or PMA approvals are essential steps toward market entry and success.

Opportunity Rollup

Odds of Success

3.7

Peak Market Share

4.7

Segment CAGR

3.0%

Market Segment

Orthopedic Devices

Market Sub Segment

Biomaterials for Orthopedic Surgery

Key Takeaway

Acuitive Technologies, with its innovative CITREGEN biomaterial and experienced leadership, is well-positioned to address significant needs in orthopedic surgery, though it faces challenges in a competitive and regulated market.